{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:13:53Z","timestamp":1778818433829,"version":"3.51.4"},"reference-count":26,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"unspecified","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"name":"EME","award":["14\/200\/18"],"award-info":[{"award-number":["14\/200\/18"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Osteogenesis imperfecta (OI) is a rare genetic disease associated with multiple fractures throughout life. It is often treated with osteoporosis medications but their effectiveness at preventing fractures is unknown. The Treatment of Osteogenesis Imperfecta with Parathyroid Hormone and Zoledronic Acid trial will determine if therapy with teriparatide (TPTD) followed by zoledronic acid (ZA) can reduce the risk of clinical fractures in OI.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and analysis<\/jats:title><jats:p>Individuals aged \u226518 years with a clinical diagnosis of OI are eligible to take part. At baseline, participants will undergo a spine X-ray, and have bone mineral density (BMD) measured by dual-energy X-ray absorptiometry (DXA) at the spine and hip. Information on previous fractures and previous bone targeted treatments will be collected. Questionnaires will be completed to assess pain and other aspects of health-related quality of life (HRQoL). Participants will be randomised to receive a 2-year course of TPTD injections 20 \u00b5g daily followed by a single intravenous infusion of 5\u2009mg ZA, or to receive standard care, which will exclude the use of bone anabolic drugs. Participants will be followed up annually, have a repeat DXA at 2 years and at the end of study. Spine X-rays will be repeated at the end of study. The duration of follow-up will range between 2 and 8\u2009years. The primary endpoint will be new clinical fractures confirmed by X-ray or other imaging. Secondary endpoints will include participant reported fractures, BMD and changes in pain and HRQoL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Ethics and dissemination<\/jats:title><jats:p>The study received ethical approval in December 2016. Following completion of the trial, a manuscript will be submitted to a peer-reviewed journal. The results will inform clinical practice by determining if TPTD\/ZA can reduce the risk of fractures in OI compared with standard care.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration number<\/jats:title><jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"isrctn\" specific-use=\"clinicaltrial pre-results\" xlink:href=\"ISRCTN15313991\">ISRCTN15313991<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2023-078164","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T17:36:24Z","timestamp":1700674584000},"page":"e078164","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Protocol of a randomised trial of teriparatide followed by zoledronic acid to reduce fracture risk in adults with osteogenesis imperfecta"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"isrctn15313991","registry":"10.18810\/isrctn","type":"preResults"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7907-3792","authenticated-orcid":false,"given":"Jannie D","family":"Hald","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5459-6178","authenticated-orcid":false,"given":"Catriona","family":"Keerie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6494-4903","authenticated-orcid":false,"given":"Christopher J","family":"Weir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad K","family":"Javaid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wayne","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Osborne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8712-7199","authenticated-orcid":false,"given":"Bente L","family":"Langdahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2804-7586","authenticated-orcid":false,"given":"Stuart H","family":"Ralston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,11,22]]},"reference":[{"key":"2023112209351699000_13.11.e078164.1","doi-asserted-by":"crossref","unstructured":"Ralston SH , Gaston MS . Management of Osteogenesis Imperfecta. Front Endocrinol (Lausanne) 2019;10:924. doi:10.3389\/fendo.2019.00924","DOI":"10.3389\/fendo.2019.00924"},{"key":"2023112209351699000_13.11.e078164.2","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.16.2.101"},{"key":"2023112209351699000_13.11.e078164.3"},{"key":"2023112209351699000_13.11.e078164.4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11657-011-0054-z","article-title":"Bone mass, bone markers and prevalence of fractures in adults with Osteogenesis Imperfecta","volume":"6","author":"Wekre","year":"2011","journal-title":"Arch Osteoporos"},{"key":"2023112209351699000_13.11.e078164.5","doi-asserted-by":"publisher","DOI":"10.1016\/S8756-3282(00)00269-6"},{"key":"2023112209351699000_13.11.e078164.6","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.bone.2004.02.023","article-title":"Bone turnover markers in patients with Osteogenesis Imperfecta","volume":"34","author":"Braga","year":"2004","journal-title":"Bone"},{"key":"2023112209351699000_13.11.e078164.7","doi-asserted-by":"publisher","DOI":"10.1007\/s002239900600"},{"key":"2023112209351699000_13.11.e078164.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2009.10.037"},{"key":"2023112209351699000_13.11.e078164.9","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-008-9113-x"},{"key":"2023112209351699000_13.11.e078164.10","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bone.2013.11.023","article-title":"Mineral particle size in children with Osteogenesis Imperfecta type I is not increased independently of specific collagen mutations","volume":"60","author":"Fratzl-Zelman","year":"2014","journal-title":"Bone"},{"key":"2023112209351699000_13.11.e078164.11","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1210\/jc.2016-1334","article-title":"Non-lethal type VIII Osteogenesis Imperfecta has elevated bone matrix mineralization","volume":"101","author":"Fratzl-Zelman","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2023112209351699000_13.11.e078164.12","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.bone.2014.12.023","article-title":"Unique Micro- and Nano-scale mineralization pattern of human Osteogenesis Imperfecta type VI bone","volume":"73","author":"Fratzl-Zelman","year":"2015","journal-title":"Bone"},{"key":"2023112209351699000_13.11.e078164.13","doi-asserted-by":"crossref","unstructured":"Dwan K , Phillipi CA , Steiner RD , et al . Bisphosphonate therapy for Osteogenesis Imperfecta. Cochrane Database Syst Rev 2016;10:CD005088. doi:10.1002\/14651858.CD005088.pub4","DOI":"10.1002\/14651858.CD005088.pub4"},{"key":"2023112209351699000_13.11.e078164.14","doi-asserted-by":"crossref","unstructured":"Dwan K , Phillipi CA , Steiner RD , et al . Bisphosphonate therapy for Osteogenesis Imperfecta. Cochrane Database Syst Rev 2014:CD005088. doi:10.1002\/14651858.CD005088.pub3","DOI":"10.1002\/14651858.CD005088.pub3"},{"key":"2023112209351699000_13.11.e078164.15","doi-asserted-by":"crossref","unstructured":"Phillipi CA , Remmington T , Steiner RD . Bisphosphonate therapy for Osteogenesis Imperfecta. Cochrane Database Syst Rev 2008:CD005088. doi:10.1002\/14651858.CD005088.pub2","DOI":"10.1002\/14651858.CD005088.pub2"},{"key":"2023112209351699000_13.11.e078164.16","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/jbmr.2410","article-title":"Bisphosphonates for the prevention of fractures in Osteogenesis Imperfecta: meta-analysis of placebo-controlled trials","volume":"30","author":"Hald","year":"2015","journal-title":"J Bone Miner Res"},{"key":"2023112209351699000_13.11.e078164.17","doi-asserted-by":"publisher","DOI":"10.1016\/S8756-3282(00)00376-8"},{"key":"2023112209351699000_13.11.e078164.18","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1172\/JCI71101","article-title":"Evaluation of Teriparatide treatment in adults with Osteogenesis Imperfecta","volume":"124","author":"Orwoll","year":"2014","journal-title":"J Clin Invest"},{"key":"2023112209351699000_13.11.e078164.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(98)00081-X"},{"key":"2023112209351699000_13.11.e078164.20","first-page":"167","article-title":"The Stanford health assessment questionnaire: a review of its history, issues, progress, and documentation","volume":"30","author":"Bruce","year":"2003","journal-title":"J Rheumatol"},{"key":"2023112209351699000_13.11.e078164.21","doi-asserted-by":"publisher","DOI":"10.3109\/07853890109002087"},{"key":"2023112209351699000_13.11.e078164.22","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1526-4637.2009.00774.x","article-title":"\u201cThe brief pain inventory and its \"pain at its worst in the last 24 hours\" item: clinical trial Endpoint considerations\u201d","volume":"11","author":"Atkinson","year":"2010","journal-title":"Pain Med"},{"key":"2023112209351699000_13.11.e078164.23","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(89)90047-4"},{"key":"2023112209351699000_13.11.e078164.24","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/crj.12092","article-title":"Spinal deformities and lung function in adults with Osteogenesis Imperfecta","volume":"8","author":"Wekre","year":"2014","journal-title":"Clin Respir J"},{"key":"2023112209351699000_13.11.e078164.25","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2003.18.1.126"},{"key":"2023112209351699000_13.11.e078164.26","doi-asserted-by":"crossref","unstructured":"Schulz KF , Altman DG , Moher D , et al . Statement: updated guidelines for reporting parallel group randomised trials. Trials 2010;11:32. doi:10.1186\/1745-6215-11-32","DOI":"10.1186\/1745-6215-11-32"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-078164","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T17:36:37Z","timestamp":1700674597000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-078164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":26,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11,22]]},"published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1136\/bmjopen-2023-078164"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-078164","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11]]}}}